The proof is in the pudding: patient engagement in studying cannabidiol in mild cognitive impairment

The proof is in the pudding: patient engagement in studying cannabidiol in mild cognitive impairment

Abstract Background Patient engagement (PE) in clinical trials has gained importance yet remains uncommon, particularly in patients with mild cognitive impairment (MCI), a critical precursor to Alzheimer’s disease (AD). Cannabidiol (CBD) shows potential in slowing MCI progression due to its neuropro...

ver descrição completa

Detalhes bibliográficos
Main Authors:	Antonia Keck, Julia-Sophia Scheuermann, Petra Scheerbaum, Elmar Graessel, Kirsten R. Müller-Vahl
Formato:	Artigo
Idioma:	English
Publicado em:	BMC 2025-01-01
Colecção:	BMC Complementary Medicine and Therapies
Assuntos:	Mild cognitive impairment Alzheimer’s disease Cannabidiol Cannabis-based medicine Patient engagement Patient and public involvement
Acesso em linha:	https://doi.org/10.1186/s12906-025-04753-w

Registos relacionados

Disposition of Cannabidiol Metabolites in Serum and Urine from Healthy Individuals Treated with Pharmaceutical Preparations of Medical Cannabis
Por: Ana Pilar Pérez-Acevedo, et al.
Publicado em: (2020-12-01)

Individualised computerised cognitive training (iCCT) for community-dwelling people with mild cognitive impairment (MCI): results on cognition in the 6-month intervention period of a randomised controlled trial (MCI-CCT study)
Por: Elmar Graessel, et al.
Publicado em: (2024-10-01)

3D Printed Bigel: A Novel Delivery System for Cannabidiol-Rich Hemp Extract
Por: Anna Gościniak, et al.
Publicado em: (2024-11-01)

Cannabis Contaminants Limit Pharmacological Use of Cannabidiol
Por: Zackary Montoya, et al.
Publicado em: (2020-09-01)

El cannabidiol y sus indicaciones en psiquiatría
Por: Juan Fernando Muñoz Ramírez
Publicado em: (2021-03-01)

Co-Dispersion Delivery Systems with Solubilizing Carriers Improving the Solubility and Permeability of Cannabinoids (Cannabidiol, Cannabidiolic Acid, and Cannabichromene) from <i>Cannabis sativa</i> (Henola Variety) Inflorescences
Por: Anna Stasiłowicz-Krzemień, et al.
Publicado em: (2023-09-01)

Predictors of institutionalization in users of day care facilities with mild cognitive impairment to moderate dementia
Por: Klara Spiegl, et al.
Publicado em: (2021-09-01)

Plasma Pharmacokinetics of Cannabidiol Following Oral Administration of Cannabidiol Oil to Dairy Calves
Por: Kelsey Meyer, et al.
Publicado em: (2022-01-01)

Reasons for using cannabidiol: a cross-sectional study of French cannabidiol users
Por: Davide Fortin, et al.
Publicado em: (2021-10-01)

Cannabidiol use and perceptions in France: a national survey
Por: Clémence Casanova, et al.
Publicado em: (2022-08-01)

Pharmacovigilance on cannabidiol as an antiepileptic agent
Por: Ilaria Ammendolia, et al.
Publicado em: (2023-02-01)

Patterns of cannabidiol use among marijuana users in the United States
Por: Ji-Yeun Park
Publicado em: (2025-02-01)

The Effects of Cannabidiol on the Driving Performance of Healthy Adults: A Pilot RCT
Por: Toni Marie Rudisill, MS, PhD, et al.
Publicado em: (2023-03-01)

Cannabis sativa and Cannabidiol: A Therapeutic Strategy for the Treatment of Neurodegenerative Diseases?
Por: Milena de Barros Viana, et al.
Publicado em: (2022-11-01)

Cannabidiol Content and In Vitro Biological Activities of Commercial Cannabidiol Oils and Hemp Seed Oils
Por: Masashi Kitamura, et al.
Publicado em: (2020-09-01)

Effects of Cannabidiol on Locomotor Activity
Por: Fabrizio Calapai, et al.
Publicado em: (2022-04-01)

A Balanced Approach for Cannabidiol Use in Chronic Pain
Por: Donovan A. Argueta, et al.
Publicado em: (2020-04-01)

Comparative Metabolomic Profiling of the Metabolic Differences of Δ9-Tetrahydrocannabinol and Cannabidiol
Por: Qianru Rao, et al.
Publicado em: (2022-11-01)

Current state of knowledge on the use of cannabidiol (CBD) in various medical conditions
Por: Zuzanna Lubczyńska, et al.
Publicado em: (2023-06-01)

In Vitro Evidence of Selective Pro-Apoptotic Action of the Pure Cannabidiol and Cannabidiol-Rich Extract
Por: Paweł Śledziński, et al.
Publicado em: (2023-12-01)

Pharmacokinetics behavior of four cannabidiol preparations following single oral administration in dogs
Por: Sasithorn Limsuwan, et al.
Publicado em: (2024-04-01)

Isolation, Purification, and Antimicrobial Characterization of Cannabidiolic Acid and Cannabidiol from <i>Cannabis sativa</i> L.
Por: Laura Daniela Martinenghi, et al.
Publicado em: (2020-06-01)

Selling cannabidiol products in Canada: A framing analysis of advertising claims by online retailers
Por: Marco Antonio Zenone, et al.
Publicado em: (2021-07-01)

Cannabidiol as a Treatment for Chronic Pain: A Survey of Patients’ Perspectives and Attitudes
Por: Schilling JM, et al.
Publicado em: (2021-05-01)

Disposition of Phytocannabinoids, Their Acidic Precursors and Their Metabolites in Biological Matrices of Healthy Individuals Treated with Vaporized Medical Cannabis
Por: Francesco Paolo Busardò, et al.
Publicado em: (2021-01-01)

Acceptability of and attitudes to the therapeutic use of cannabis and cannabidiol in people with Parkinson’s disease: A French survey
Por: Tangui Barré, et al.
Publicado em: (2024-01-01)

Combinations of Cannabidiol and Δ<sup>9</sup>-Tetrahydrocannabinol in Reducing Chemotherapeutic Induced Neuropathic Pain
Por: Diana E. Sepulveda, et al.
Publicado em: (2022-10-01)

Total cannabidiol (CBD) concentrations and yields from traditional extraction methods: Percolation vs. maceration
Por: Jason Wilson, et al.
Publicado em: (2022-10-01)

Cannabidiol (CBD) in the Self-Treatment of Depression-Exploratory Study and a New Phenomenon of Concern for Psychiatrists
Por: Gniewko Wieckiewicz, et al.
Publicado em: (2022-03-01)

Δ 9-Tetrahydrocannabinol Toxicity and Validation of Cannabidiol on Brain Dopamine Levels: An Assessment on Cannabis Duplicity
Por: Swapnali Chetia, et al.
Publicado em: (2020-08-01)

Effects of Chronic Cannabidiol Treatment in the Rat Chronic Unpredictable Mild Stress Model of Depression
Por: Zsolt Gáll, et al.
Publicado em: (2020-05-01)

Cannabis Effects on Driving Performance: Clinical Considerations
Por: Brianna Costales, et al.
Publicado em: (2023-01-01)

Production of Cannabidiol Acid Synthase by Chassis Pichia pastoris and of Its Catalytic Activity Analysis
Por: Tingli NIU, et al.
Publicado em: (2023-10-01)

What are the informational pathways that shape people’s use of cannabidiol for medical purposes?
Por: Marco A. Zenone, et al.
Publicado em: (2021-05-01)

A phase III multisite randomised controlled trial to compare the efficacy of cannabidiol to placebo in the treatment of cannabis use disorder: the CBD-CUD study protocol
Por: Anjali K. Bhardwaj, et al.
Publicado em: (2024-03-01)

The Potential of Cannabidiol for Treating Canine Atopic Dermatitis
Por: Ana F. Bizarro, et al.
Publicado em: (2025-02-01)

The Influence of Cannabidiol on the Pharmacokinetics of Methylphenidate in Healthy Subjects
Por: John S. Markowitz, et al.
Publicado em: (2022-11-01)

Safety assessment of female sexual hygiene product containing cannabidiol in new zealand white rabbit and clinical trial
Por: Atiwut Kamudhamas, et al.
Publicado em: (2024-12-01)

Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age
Por: José A. Crippa, et al.
Publicado em: (2018-09-01)

Is cannabidiol a drug acting on unconventional targets to control drug‐resistant epilepsy?
Por: Luisa Rocha, et al.
Publicado em: (2020-03-01)